Nuclera

Cambridge, United Kingdom · Founded 2013 · Privately Held (backing)

Developer of a protein prototyping system designed to accelerate drug discovery workflows. Nuclera is based in Cambridge, United Kingdom and was founded in 2013. It was valued at $155 million at its Series B in Jul 2022, the last priced event on record. It has raised $166 million across 9 recorded rounds; the latest was an $87 million Series C in Jan 2026.

PMV mark · valuation
$154.5M
Oct 2026
Priced at
its Series B
Jul 2022
Total raised
$166.1M
Last round
Later Stage VC (Series C)
Jan 2026

Leadership

5
+ 6 more people (board, observers, advisors) · free account shows everyone

Membership and data by Private Market View

Who runs Nuclera

11 people are listed on the Nuclera team: 5 executives and 6 board members, including Gordon McInroy Ph.D (Co-Founder) and Michael Chen Ph.D (Co-Founder). 7 of them have a verified direct contact on file.

Free account
More of Nuclera with a free account
  • ·Post-money valuations for 2 rounds
  • ·The complete investor list: 22 names
  • ·Watch Nuclera: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Contact database
Verified contact details, revealed on demand

7 of the people at Nuclera have a verified contact on file. Plus members reveal 10 contacts a month, Pro members 200.

Unlock contact reveals

Membership and data by Private Market View